NEW YORK (Reuters Health) – Using a new approach to detect tumor-associated plasma proteins, Canadian researchers have discovered a novel biomarker that may improve the diagnosis of lung cancer in the preclinical stage.
As principal investigator Dr. Stephen Lam and colleagues explain in the Journal of Clinical Oncology published online on May 4, their strategy












